Cell Based Assays Market: Growth, Size, Share, and Trends
Report Code
BT 2486
Published in
Apr, 2025, By MarketsandMarkets™
Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030
USD 25.77 BN
MARKET SIZE, 2030
CAGR 7.3%
(2025-2030)
448
REPORT PAGES
564
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The cell-based assays (CBA) market is projected to reach USD 25.77 billion by 2030 from USD 18.13 billion in 2025 at a CAGR of 7.3% during the forecast period. The major factors driving the growth of this market include growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, rising prevalence of cancer, and government support and funding for cell-based research.
KEY TAKEAWAYS
-
BY REGIONThe North America cell-based assays market dominated, with a share of 40.3% in 2024.. The availability of government and private funding for life science research, the growing penetration of CROs, comprehensive drug development regulations, are some factors supporting the growth of the North American cell-based assays market.
-
BY OFFERINGBy offering, the consumables segment accounted for the largest share of 52.2% of the market in 2024. This dominance can primarily be attributed to the growing focus on developing advanced cell-based therapies and the rising demand for high-quality materials for cell-based research.
-
BY TECHNOLOGYBy technology, the flow cytometry segment dominated the cell-based assays market in 2024, attributed to the wide usage of flow cytometry in cell analysis and growth in cell-based research.
-
BY APPLICATIONBy application, the drug discovery segment is expected to register the highest CAGR of 7.9%. owing to the increasing need for advanced cell-based therapies and rising investments and funding for cell-based research.
-
COMPETITIVE LANDSCAPEPlayers in the global cell-based assays market have employed various strategies to expand their footprints and increase their market shares. The key strategies major players adopt in the cell-based assays market include product & service launches, expansions, acquisitions, partnerships, and collaborations.
The cell-based assays market is witnessing steady growth, driven by advancements in high-content screening technologies, automation, and increasing adoption of cell-based models in drug discovery and toxicity testing. Rising demand for predictive in vitro testing, growing focus on biologics and personalized medicine, and expansion of cell-based research in cancer and immunology are key factors fueling market expansion.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The cell-based assays market is being shaped by the growing shift toward precision medicine and the integration of AI-driven technologies. Increasing adoption of targeted therapies, companion diagnostics, and cancer-focused research is driving demand for advanced cell-based assays in drug discovery and diagnostic applications. At the same time, Artificial Intelligence (AI) and Machine Learning (ML) are transforming assay workflows by enabling high-throughput data analysis, enhancing accuracy, and improving predictive insights. These trends are accelerating innovation and expanding the role of cell-based assays across research and clinical applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Government support and funding for cell-based research
-
Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery
RESTRAINTS
Impact
Level
Level
-
High cost of instruments and restrictions imposed by product end-user licenses for reagents
-
Lack of standardization of protocols used in cell-based assays
OPPORTUNITIES
Impact
Level
Level
-
Growing applications of cell-based assays in chronic diseases and personalized medicine
-
Rising adoption of AI in drug discovery and cell analysis
CHALLENGES
Impact
Level
Level
-
Complexities in assay designs
-
Shortage of skilled professionals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing government support and funding for cell-based research
Cell-based assays are used to measure cell viability, health, proliferation, and apoptosis. These assays are widely utilized in drug discovery and development. A significant factor driving the growth of the market is the increasing funding and investments aimed at developing advanced cell-based therapeutics. Additionally, strong government support for accelerating cell-based research plays a crucial role in this growth. For instanv, in March 2025, the California Institute for Regenerative Medicine (CIRM) approved funding of USD 425 million for research in the discovery, preclinical, and clinical stages.
Restraint: High cost of instruments and restrictions imposed by product end-user licenses for reagents
The high costs associated with cell-based assay instruments and the restrictions imposed by product end-user licenses for reagents are significant restraints to the growth of the cell-based assays market. The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell-based assays has increased their reliability. However, the initial investment required to acquire the necessary instruments can be substantial, deterring smaller research facilities and resource-limited organizations from adopting these technologies. Moreover, the time and cost involved in each HTS process are directly proportional to the target molecule’s complexity; consequently, the higher the complexity, the greater the cost.
Opportunity: Growing applications of cell-based assays in personalized medicine
Cell-based assays are widely used for drug discovery and basic research. The wide applications of cell-based assays in drug discovery are expected to create significant growth opportunities for players in the market. Additionally, cell-based assays provide valuable insights into the mechanism of cells associated with chronic diseases and offer more accurate disease management and drug development approaches. In cancer research, cell-based assays are used to study the response of tumor cells to potential treatment. Thus, the growing applications of cell-based assays in the management of chronic conditions are anticipated to support market growth in the coming years.
Challenge: Complexities in assay designs
Cell-based assays are associated with some complexities in assay design due to interactions in cellular factors and processes. The development of accurate and reliable assays to provide precise data is a complex task. Complexities with assay design arise due to various factors, such as cell type selection, assay protocols, culture conditions, and endpoint measurement. Designing assays that can mimic complex cellular environments requires careful consideration and optimization. However
cell-based-assays-market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Whole-cell phenotypic high-throughput screening (HTS) across 1.8M compounds against kinetoplastid parasites using intracellular cell-based assays to triage anti-parasitic hits. | Regulator-accepted cell-based potency for lot release | Stability-indicating control that reduces batch failures and supports global supply. |
 |
Discovery program for DGKα/ζ inhibitor (BMS-986408) characterized with cell-based activation assays (T-cell signaling/phenotyping). | Validated activation/cytotoxicity assays ensure lot-to-lot functional consistency | Faster release decisions and scalable multi-site manufacturing. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The market ecosystem comprises product/service providers and end users, such as pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations (CROs). Manufacturers develop and distribute cell-based assay products while navigating regulations set by bodies like the FDA and EMA, ensuring quality and compliance throughout the supply chain. This intricate network facilitates the production, research, and development of biopharmaceuticals and enables advancements in biopharmaceutical manufacturing.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Cell-based Assays Consumables Market, By Type
In 2024, the reagents segment held the largest share of the consumables market. The increasing emphasis on drug discovery & development, particularly in areas such as oncology, neurology, and infectious diseases, is fueling the need for effective cell-based assays and, consequently, driving the demand for specialized reagents. Moreover, the rising adoption of regenerative medicine and cell therapy approaches has created a surge in the demand for cell-based reagents to evaluate the efficacy and safety of these innovative treatments.
Cell-based Assays Market, By Application
In 2024, the drug discovery segment held the largest share of the application market. Cell-based assays are considered a powerful tool for analyzing compounds in high-throughput drug discovery. These assays are used in more than half of the high-throughput drug screenings for target validation and absorption, distribution, metabolism, elimination, and toxicity (ADMET) studies in the early stages of drug discovery. Cell-based assays are also used to identify potential drug targets, assess the efficacy of drug candidates, and study the toxicity of drugs.
Cell-based Assays Market, By End User
The pharmaceutical & biotechnology companies segment accounted for the largest share of the cell-based assays market in 2024. Pharmaceutical & biotechnology companies are the largest end users of cell-based assays. The demand for cell-based assays in this end-user segment is driven by the growth in the number of R&D activities for the development of new pharma and biotech drugs and therapies coupled with the adoption of cell-based assays in these companies.
REGION
Asia Pacific to be fastest-growing region in global cell-based assays market during forecast period
The Asia Pacific cell-based assays market is expected to register the highest CAGR during the forecast period, driven by rising government initiatives to increase funding in biopharmaceuticals, growing R&D spending, public-private partnerships for life science research, and increasing drug discovery and development studies. Additionally, the rising geriatric population, growth of the healthcare industry, and the availability of basic infrastructure for R&D will support market growth.
cell-based-assays-market: COMPANY EVALUATION MATRIX
In the cell-based assays market matrix, Danaher Corporation (Star) leads with a strong market share and an extensive portfolio spanning assay kits, instruments, reagents, and analytical platforms. Its robust global presence, continuous product innovation, and integration of advanced automation and imaging technologies have strengthened its leadership in supporting drug discovery, toxicity testing, and cell analysis research. Sartorius AG (Emerging Leader) is gaining traction through its focus on integrated cell analysis solutions, high-performance instruments, and cell culture technologies that enhance assay reproducibility and throughput. Sartorius demonstrates strong potential to move toward the leaders’ quadrant as adoption of automated and high-content cell-based assays continues to rise across pharmaceutical and biotechnology sectors.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- BD (US)
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (US)
- Lonza (Switzerland)
- Charles River Laboratories (US)
- Bio-Rad Laboratories, Inc. (US)
- Revvity (US)
- Sartorius AG (Germany)
- Corning Incorporated (US)
- Promega Corporation (US)
- Cell Signaling Technology, Inc. (US)
- Eurofins Scientific (Luxembourg)
- Enzo Biochem, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 17.36 Billion |
| Market Forecast in 2030 (Value) | USD 25.77 Billion |
| Growth Rate | CAGR of 7.3% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: cell-based-assays-market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Europe Cell-based Assays Products Market |
|
|
| Client Identification in North America & Europe |
|
|
RECENT DEVELOPMENTS
- April 2025 : BD Biosciences launched the BD FACSDiscover A8 Cell Analyzer, a spectral cell analyzer with real-time imaging capabilities. This system integrates BD CellView Image Technology with BD SpectralFX Technology, enabling researchers to simultaneously capture high-resolution images and perform spectral flow cytometry.
- February 2025 : Intertek established its regional headquarters in Riyadh, the Kingdom of Saudi Arabia, to strengthen its portfolio of cell-based assays services and highlight the company’s role in achieving the goals of Saudi Arabia’s Vision 2030.
- January 2025 : Merck KGaA acquired HUB Organoids Holding B.V. (HUB), a pioneer in organoid technology. The acquisition aims to strengthen Merck’s capabilities in 3D cell culture and organoid-based assays, enhancing drug discovery and development processes.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
38
2
RESEARCH METHODOLOGY
43
3
EXECUTIVE SUMMARY
55
4
PREMIUM INSIGHTS
59
5
MARKET OVERVIEW
Cell-based assays revolutionize drug discovery amid rising AI adoption and government-backed research initiatives.
62
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
GROWING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT AND INCREASING PREFERENCE FOR CELL-BASED ASSAYS IN DRUG DISCOVERY
5.2.1.2
GOVERNMENT SUPPORT AND FUNDING FOR CELL-BASED RESEARCH
5.2.1.3
GROWING EFFORTS TO CURTAIL ANIMAL-BASED STUDIES
5.2.1.4
RISING PREVALENCE OF CANCER
5.2.1.5
ALLIANCES TO ACCELERATE INNOVATIONS IN DRUG DISCOVERY
5.2.2
RESTRAINTS
5.2.2.1
HIGH COST OF INSTRUMENTS AND RESTRICTIONS IMPOSED BY PRODUCT END-USER LICENSES FOR REAGENTS
5.2.2.2
LACK OF STANDARDIZATION OF PROTOCOLS USED IN CELL-BASED ASSAYS
5.2.3
OPPORTUNITIES
5.2.3.1
GROWING APPLICATIONS OF CELL-BASED ASSAYS IN CHRONIC DISEASES AND PERSONALIZED MEDICINE
5.2.3.2
GROWTH OPPORTUNITIES IN EMERGING ECONOMIES
5.2.3.3
RISING ADOPTION OF AI IN DRUG DISCOVERY AND CELL ANALYSIS
5.2.4
CHALLENGES
5.2.4.1
COMPLEXITIES IN ASSAY DESIGNS
5.2.4.2
SHORTAGE OF SKILLED PROFESSIONALS
5.3
TECHNOLOGY ANALYSIS
5.3.1
KEY TECHNOLOGIES
5.3.1.1
FLOW CYTOMETRY
5.3.1.2
HIGH-THROUGHPUT SCREENING
5.3.1.3
HIGH-CONTENT SCREENING
5.3.1.4
LABEL-FREE DETECTION
5.3.2
COMPLEMENTARY TECHNOLOGIES
5.3.2.1
ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
5.3.3
ADJACENT TECHNOLOGIES
5.3.3.1
NANOTECHNOLOGY
5.4
VALUE CHAIN ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021–2024
5.5.2
AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024
5.6
ECOSYSTEM ANALYSIS
5.6.1
RAW MATERIAL VENDORS
5.6.2
PRODUCT/SERVICE VENDORS
5.6.3
END USERS
5.6.4
REGULATORY BODIES
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8
PATENT ANALYSIS
5.8.1
NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE, 2014–2025
5.9
KEY CONFERENCES & EVENTS, 2025–2026
5.10
TARIFF AND REGULATORY LANDSCAPE
5.10.1
TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.3
REGULATORY FRAMEWORK
5.10.3.1
NORTH AMERICA
5.10.3.2
EUROPE
5.10.3.3
ASIA PACIFIC
5.10.3.4
REST OF THE WORLD
5.11
PORTER’S FIVE FORCES ANALYSIS
5.11.1
THREAT OF NEW ENTRANTS
5.11.2
THREAT OF SUBSTITUTES
5.11.3
BARGAINING POWER OF SUPPLIERS
5.11.4
BARGAINING POWER OF BUYERS
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
5.12
KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2
BUYING CRITERIA
5.13
INVESTMENT AND FUNDING SCENARIO
5.14
TRADE ANALYSIS
5.14.1
IMPORT DATA
5.14.2
EXPORT DATA
5.15
IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET
5.16
IMPACT OF 2025 US TARIFF ON CELL-BASED ASSAYS MARKET
5.16.1
INTRODUCTION
5.16.2
KEY TARIFF RATES
5.16.3
PRICE IMPACT ANALYSIS
5.16.4
IMPACT ON COUNTRY/REGION
5.16.4.1
US
5.16.4.2
EUROPE
5.16.4.3
ASIA PACIFIC
5.16.5
IMPACT ON END-USE INDUSTRIES
5.16.5.1
PHARMACEUTICAL & BIOTECH COMPANIES
5.16.5.2
CONTRACT RESEARCH ORGANIZATIONS (CROS)
5.16.5.3
ACADEMIC & RESEARCH INSTITUTES
6
CELL-BASED ASSAYS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 134 Data Tables
107
6.1
INTRODUCTION
6.2
CONSUMABLES
6.2.1
REAGENTS
6.2.1.1
HIGH DEMAND FOR REAGENTS IN RESEARCH APPLICATIONS TO PROPEL MARKET GROWTH
6.2.2
ASSAY KITS
6.2.2.1
REPORTER GENE ASSAYS
6.2.2.2
CELL GROWTH ASSAYS
6.2.2.3
SECONDARY MESSENGER ASSAYS
6.2.2.4
CELL DEATH ASSAYS
6.2.2.5
OTHER ASSAY KITS
6.2.3
MICROPLATES
6.2.3.1
DEMAND FOR MICROPLATES IN ASSAY DEVELOPMENT TO DRIVE MARKET
6.2.4
CELL LINES
6.2.4.1
IMMORTALIZED CELL LINES
6.2.4.2
PRIMARY CELL LINES
6.2.4.3
STEM CELL LINES
6.2.5
PROBES & LABELS
6.2.5.1
GROWING NEED FOR EFFECTIVE CELL LABELING TO BOOST DEMAND
6.2.6
OTHER CONSUMABLES
6.3
INSTRUMENTS
6.3.1
AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH
6.4
SERVICES
6.4.1
GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH
6.5
SOFTWARE
6.5.1
INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS TO DRIVE GROWTH
7
CELL-BASED ASSAYS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 29 Data Tables
171
7.1
INTRODUCTION
7.2
FLOW CYTOMETRY
7.2.1
WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO DRIVE MARKET
7.3
HIGH-THROUGHPUT SCREENING
7.3.1
INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
7.4
LABEL-FREE DETECTION
7.4.1
GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND
7.5
OTHER TECHNOLOGIES
8
CELL-BASED ASSAYS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 51 Data Tables
186
8.1
INTRODUCTION
8.2
DRUG DISCOVERY
8.2.1
TOXICITY STUDIES
8.2.1.1
INCREASING DEMAND FOR CELL-BASED ASSAYS IN TOXICITY TESTING TO FUEL GROWTH
8.2.2
PHARMACOKINETIC STUDIES
8.2.2.1
GROWING FOCUS ON ADME STUDIES IN PHARMACOKINETICS TO PROPEL DEMAND FOR CELL-BASED ASSAYS
8.2.3
PHARMACODYNAMIC STUDIES
8.2.3.1
ADVANTAGES OF CELL-BASED ASSAYS IN PHARMACODYNAMICS TO PROPEL GROWTH
8.3
BASIC RESEARCH
8.3.1
INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES
8.4
GENETIC STUDIES
8.4.1
INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET
8.5
OTHER APPLICATIONS
9
CELL-BASED ASSAYS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 23 Data Tables
214
9.1
INTRODUCTION
9.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1
GROWTH IN R&D EFFORTS TOWARD CELL-BASED ASSAYS IN PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTORS TO DRIVE MARKET
9.3
CONTRACT RESEARCH ORGANIZATIONS
9.3.1
GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH
9.4
ACADEMIC & RESEARCH INSTITUTES
9.4.1
RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE MARKET
10
CELL-BASED ASSAYS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 231 Data Tables.
228
10.1
INTRODUCTION
10.2
NORTH AMERICA
10.2.1
MACROECONOMIC OUTLOOK
10.2.2
US
10.2.2.1
ESTABLISHED PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS TO DRIVE MARKET
10.2.3
CANADA
10.2.3.1
INCREASING FUNDING AND INVESTMENTS TO DRIVE MARKET
10.3
EUROPE
10.3.1
MACROECONOMIC OUTLOOK
10.3.2
GERMANY
10.3.2.1
TO DOMINATE CELL-BASED ASSAYS MARKET IN EUROPE
10.3.3
UK
10.3.3.1
GROWING CANCER RESEARCH FUNDING TO INCREASE DEMAND FOR CELL-BASED ASSAYS
10.3.4
FRANCE
10.3.4.1
GROWING BIOTECHNOLOGY SECTOR TO DRIVE MARKET
10.3.5
ITALY
10.3.5.1
GROWTH OF PHARMACEUTICAL INDUSTRY TO BOOST MARKET
10.3.6
SPAIN
10.3.6.1
RISING RESEARCH ACTIVITY AND INCREASING NUMBER OF BIOTECH COMPANIES TO FAVOR MARKET GROWTH
10.3.7
REST OF EUROPE
10.4
ASIA PACIFIC
10.4.1
MACROECONOMIC OUTLOOK
10.4.2
CHINA
10.4.2.1
INCREASING R&D EXPENDITURE TO FAVOR MARKET GROWTH
10.4.3
JAPAN
10.4.3.1
GOVERNMENT INITIATIVES FOR DRUG INNOVATION TO SUPPORT MARKET GROWTH
10.4.4
INDIA
10.4.4.1
INCREASING INVESTMENTS IN R&D AND FUNDING FOR LIFE SCIENCE RESEARCH TO PROPEL MARKET
10.4.5
AUSTRALIA
10.4.5.1
BOOMING LIFE SCIENCE SECTOR TO PROPEL MARKET
10.4.6
SOUTH KOREA
10.4.6.1
INCREASING STRATEGIC ALLIANCES TO SUPPORT MARKET GROWTH
10.4.7
REST OF ASIA PACIFIC
10.5
LATIN AMERICA
10.5.1
MACROECONOMIC OUTLOOK
10.5.2
BRAZIL
10.5.2.1
BRAZIL TO HOLD LARGEST SHARE OF LATIN AMERICAN MARKET
10.5.3
MEXICO
10.5.3.1
GOVERNMENT SUPPORT FOR BIOPHARMACEUTICAL PRODUCTION TO SUPPORT MARKET GROWTH
10.5.4
REST OF LATIN AMERICA
10.6
MIDDLE EAST
10.6.1
MACROECONOMIC OUTLOOK
10.6.2
GCC COUNTRIES
10.6.2.1
SAUDI ARABIA
10.6.2.2
UAE
10.6.2.3
REST OF GCC COUNTRIES
10.6.3
REST OF MIDDLE EAST
10.7
AFRICA
10.7.1
RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
10.7.2
MACROECONOMIC OUTLOOK
11
COMPETITIVE LANDSCAPE
Discover strategic insights and market dynamics shaping key players and emerging leaders in cell-based assays.
333
11.1
OVERVIEW
11.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025
11.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL-BASED ASSAYS MARKET
11.3
REVENUE ANALYSIS, 2020–2024
11.4
MARKET SHARE ANALYSIS, 2024
11.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1
STARS
11.5.2
EMERGING LEADERS
11.5.3
PERVASIVE PLAYERS
11.5.4
PARTICIPANTS
11.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1
COMPANY FOOTPRINT
11.5.5.2
OFFERING FOOTPRINT
11.5.5.3
TECHNOLOGY FOOTPRINT
11.5.5.4
APPLICATION FOOTPRINT
11.5.5.5
REGION FOOTPRINT
11.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1
PROGRESSIVE COMPANIES
11.6.2
RESPONSIVE COMPANIES
11.6.3
DYNAMIC COMPANIES
11.6.4
STARTING BLOCKS
11.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
11.6.5.2
COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
11.7
COMPANY VALUATION & FINANCIAL METRICS
11.8
BRAND/PRODUCT COMPARISON
11.9
COMPETITIVE SCENARIO
11.9.1
PRODUCT/SERVICE LAUNCHES & APPROVALS
11.9.2
DEALS
11.9.3
EXPANSIONS
12
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
357
12.1
INTRODUCTION
12.2
KEY PLAYERS
12.2.1
DANAHER
12.2.1.1
BUSINESS OVERVIEW
12.2.1.2
PRODUCTS/SERVICES OFFERED
12.2.1.3
RECENT DEVELOPMENTS
12.2.1.4
MNM VIEW
12.2.2
THERMO FISHER SCIENTIFIC INC.
12.2.3
MERCK KGAA
12.2.4
BD
12.2.5
AGILENT TECHNOLOGIES, INC.
12.2.6
LONZA
12.2.7
EUROFINS SCIENTIFIC
12.2.8
CHARLES RIVER LABORATORIES
12.2.9
BIO-RAD LABORATORIES, INC.
12.2.10
REVVITY
12.2.11
SARTORIUS AG
12.2.12
CORNING INCORPORATED
12.2.13
PROMEGA CORPORATION
12.2.14
CELL SIGNALING TECHNOLOGY, INC.
12.2.15
ENZO BIOCHEM INC.
12.2.16
CARNA BIOSCIENCES, INC.
12.2.17
INTERTEK GROUP PLC
12.2.18
BICO
12.3
OTHER PLAYERS
12.3.1
CELL BIOLABS, INC.
12.3.2
REACTION BIOLOGY
12.3.3
AAT BIOQUEST, INC.
12.3.4
PESTKA BIOMEDICAL LABORATORIES, INC.
12.3.5
NEUROMICS
12.3.6
BPS BIOSCIENCE, INC.
12.3.7
BELLBROOK LABS
12.3.8
PROFACGEN
12.3.9
BMG LABTECH GMBH
12.3.10
HANUGEN THERAPEUTICS
12.3.11
ALTOGEN LABS
12.3.12
BIOAGILYTIX LABS
13
APPENDIX
440
13.1
DISCUSSION GUIDE
13.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3
CUSTOMIZATION OPTIONS
13.4
RELATED REPORTS
13.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
CELL-BASED ASSAYS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 3
CELL-BASED ASSAYS MARKET: IMPACT ANALYSIS
TABLE 4
ESTIMATED EXPENDITURE BY US NIH FOR STEM CELL RESEARCH, 2019–2025
TABLE 5
PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2022 VS. 2045
TABLE 6
CELL-BASED ASSAYS MARKET: KEY DEVELOPMENTS
TABLE 7
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021–2024
TABLE 8
AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024
TABLE 9
CELL-BASED ASSAYS MARKET: ROLE OF RAW MATERIAL VENDORS
TABLE 10
CELL-BASED ASSAYS MARKET: ROLE OF PRODUCT/SERVICE VENDORS
TABLE 11
CELL-BASED ASSAYS MARKET: ROLE OF END USERS
TABLE 12
CELL-BASED ASSAYS MARKET: ROLE OF REGULATORY BODIES
TABLE 13
NUMBER OF PATENTS APPLIED AND GRANTED, JANUARY 2014–APRIL 2025
TABLE 14
INNOVATIONS AND PATENT REGISTRATIONS, 2025
TABLE 15
CELL-BASED ASSAYS MARKET: LIST OF KEY CONFERENCES & EVENTS, 2025–2026
TABLE 16
AVERAGE TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS FOR HS CODE 9027, 2024
TABLE 17
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21
CELL-BASED ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 22
BUYING CRITERIA FOR CELL-BASED ASSAY PRODUCTS, BY END USER
TABLE 23
IMPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (USD THOUSAND)
TABLE 24
IMPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (TONS)
TABLE 25
EXPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (USD THOUSAND)
TABLE 26
EXPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (TONS)
TABLE 27
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 28
CELL-BASED ASSAY PRODUCTS-RELATED TARIFF REVISION
TABLE 29
IMPACT ON END-USE APPLICATIONS OF CELL-BASED ASSAY PRODUCTS
TABLE 30
CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 31
CONSUMABLES OFFERED BY KEY COMPANIES
TABLE 32
CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 33
CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 34
NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 39
GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
REAGENTS OFFERED BY KEY COMPANIES
TABLE 41
REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 42
NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
EUROPE: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
LATIN AMERICA: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
MIDDLE EAST: REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 47
GCC COUNTRIES: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
ASSAY KITS OFFERED BY KEY COMPANIES
TABLE 49
ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 50
ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 51
NORTH AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
EUROPE: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
ASIA PACIFIC: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
LATIN AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
MIDDLE EAST: ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 56
GCC COUNTRIES: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
REPORTER GENE ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 58
NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
EUROPE: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 63
GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
CELL GROWTH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
NORTH AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
EUROPE: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67
ASIA PACIFIC: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
LATIN AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
MIDDLE EAST: CELL GROWTH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 70
GCC COUNTRIES: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
SECONDARY MESSENGER ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 72
NORTH AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
EUROPE: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
ASIA PACIFIC: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
LATIN AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
MIDDLE EAST: SECONDARY MESSENGER ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 77
GCC COUNTRIES: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
CELL DEATH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 79
NORTH AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
EUROPE: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
ASIA PACIFIC: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 82
LATIN AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
MIDDLE EAST: CELL DEATH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 84
GCC COUNTRIES: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
OTHER ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 86
NORTH AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
EUROPE: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
ASIA PACIFIC: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89
LATIN AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
MIDDLE EAST: OTHER ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 91
GCC COUNTRIES: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
MICROPLATES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 93
NORTH AMERICA: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
EUROPE: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
ASIA PACIFIC: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96
LATIN AMERICA: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
MIDDLE EAST: MICROPLATES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 98
GCC COUNTRIES: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 100
CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
NORTH AMERICA: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
EUROPE: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
ASIA PACIFIC: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
LATIN AMERICA: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
MIDDLE EAST: CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 106
GCC COUNTRIES: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
IMMORTALIZED CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 108
NORTH AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
EUROPE: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
ASIA PACIFIC: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
LATIN AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
MIDDLE EAST: IMMORTALIZED CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 113
GCC COUNTRIES: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
PRIMARY CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 115
NORTH AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
EUROPE: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
ASIA PACIFIC: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
LATIN AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
MIDDLE EAST: PRIMARY CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 120
GCC COUNTRIES: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
STEM CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 122
NORTH AMERICA: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
EUROPE: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
ASIA PACIFIC: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
LATIN AMERICA: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
MIDDLE EAST: STEM CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 127
GCC COUNTRIES: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
PROBES & LABELS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 129
NORTH AMERICA: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
EUROPE: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
ASIA PACIFIC: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132
LATIN AMERICA: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
MIDDLE EAST: PROBES & LABELS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
GCC COUNTRIES: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
OTHER CONSUMABLES OFFERED BY KEY COMPANIES
TABLE 136
OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 137
NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139
ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 142
GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 144
NORTH AMERICA: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
EUROPE: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146
ASIA PACIFIC: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
LATIN AMERICA: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
MIDDLE EAST: INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 149
GCC COUNTRIES: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 151
NORTH AMERICA: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
EUROPE: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
ASIA PACIFIC: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154
LATIN AMERICA: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
MIDDLE EAST: SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 156
GCC COUNTRIES: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 158
NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
EUROPE: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
MIDDLE EAST: SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 163
GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164
CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 165
CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2023–2030 (USD MILLION)
TABLE 166
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
EUROPE: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2023–2030 (USD MILLION)
TABLE 171
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172
CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023–2030 (USD MILLION)
TABLE 173
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
EUROPE: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 177
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023–2030 (USD MILLION)
TABLE 178
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179
CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 180
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
EUROPE: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 185
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186
OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 187
NORTH AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
EUROPE: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189
ASIA PACIFIC: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190
LATIN AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191
MIDDLE EAST: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 192
GCC COUNTRIES: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193
CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 194
CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 195
CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 196
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197
EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 199
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 201
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202
CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 203
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 204
EUROPE: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 208
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209
CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 210
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211
EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 213
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 214
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 215
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216
CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 217
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 218
EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 220
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 221
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 222
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223
CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2023–2030 (USD MILLION)
TABLE 224
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 225
EUROPE: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 227
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2023–2030 (USD MILLION)
TABLE 229
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230
CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 231
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232
EUROPE: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 234
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 236
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 237
CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 238
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 239
EUROPE: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 240
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 241
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 242
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 243
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 244
CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 245
PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)
TABLE 246
CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 247
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248
EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 249
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 250
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 251
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 252
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 253
CELL-BASED ASSAYS MARKET FOR CROS, BY REGION, 2023–2030 (USD MILLION)
TABLE 254
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 255
EUROPE: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 256
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 257
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 258
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR CROS, BY REGION, 2023–2030 (USD MILLION)
TABLE 259
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260
CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 261
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 262
EUROPE: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 263
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 264
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 265
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 266
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 267
CELL-BASED ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 268
NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 269
NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 270
NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 271
NORTH AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 272
NORTH AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273
NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 274
NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 275
NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 276
NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 277
US: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 278
US: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 279
US: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280
US: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 281
US: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 282
US: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 283
US: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 284
US: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 285
CANADA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 286
CANADA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 287
CANADA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288
CANADA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 289
CANADA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 290
CANADA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 291
CANADA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 292
CANADA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 293
EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 294
EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 295
EUROPE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 296
EUROPE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 297
EUROPE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 298
EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 299
EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 300
EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 301
EUROPE: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 302
GERMANY: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 303
GERMANY: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 304
GERMANY: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 305
GERMANY: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 306
GERMANY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 307
GERMANY: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 308
GERMANY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 309
GERMANY: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 310
UK: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 311
UK: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 312
UK: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 313
UK: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 314
UK: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 315
UK: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 316
UK: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 317
UK: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 318
FRANCE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 319
FRANCE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 320
FRANCE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321
FRANCE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 322
FRANCE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 323
FRANCE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 324
FRANCE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 325
FRANCE: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 326
ITALY: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 327
ITALY: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 328
ITALY: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329
ITALY: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 330
ITALY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 331
ITALY: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 332
ITALY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 333
ITALY: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 334
SPAIN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 335
SPAIN: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 336
SPAIN: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 337
SPAIN: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 338
SPAIN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 339
SPAIN: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 340
SPAIN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 341
SPAIN: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 342
REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 343
REST OF EUROPE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 344
REST OF EUROPE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 345
REST OF EUROPE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 346
REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 347
REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 348
REST OF EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 349
REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 350
ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 351
ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 352
ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353
ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 354
ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 355
ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 356
ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 357
ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 358
ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 359
CHINA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 360
CHINA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 361
CHINA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 362
CHINA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 363
CHINA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 364
CHINA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 365
CHINA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 366
CHINA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 367
JAPAN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 368
JAPAN: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 369
JAPAN: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 370
JAPAN: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 371
JAPAN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 372
JAPAN: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 373
JAPAN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 374
JAPAN: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 375
INDIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 376
INDIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 377
INDIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 378
INDIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 379
INDIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 380
INDIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 381
INDIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 382
INDIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 383
AUSTRALIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 384
AUSTRALIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 385
AUSTRALIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 386
AUSTRALIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 387
AUSTRALIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 388
AUSTRALIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 389
AUSTRALIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 390
AUSTRALIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 391
SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 392
SOUTH KOREA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 393
SOUTH KOREA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 394
SOUTH KOREA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 395
SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 396
SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 397
SOUTH KOREA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 398
SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 399
REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 400
REST OF ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 401
REST OF ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 402
REST OF ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 403
REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 404
REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 405
REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 406
REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 407
LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 408
LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 409
LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 410
LATIN AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 411
LATIN AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 412
LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 413
LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 414
LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 415
LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 416
BRAZIL: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 417
BRAZIL: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 418
BRAZIL: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 419
BRAZIL: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 420
BRAZIL: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 421
BRAZIL: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 422
BRAZIL: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 423
BRAZIL: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 424
MEXICO: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 425
MEXICO: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 426
MEXICO: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 427
MEXICO: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 428
MEXICO: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 429
MEXICO: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 430
MEXICO: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 431
MEXICO: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 432
REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 433
REST OF LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 434
REST OF LATIN AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 435
REST OF LATIN AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 436
REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 437
REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 438
REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 439
REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 440
MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 441
MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 442
MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 443
MIDDLE EAST: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 444
MIDDLE EAST: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 445
MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 446
MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 447
MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 448
MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 449
GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 450
GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 451
GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 452
GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 453
GCC COUNTRIES: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 454
GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 455
GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 456
GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 457
GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 458
SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 459
SAUDI ARABIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 460
SAUDI ARABIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 461
SAUDI ARABIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 462
SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 463
SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 464
SAUDI ARABIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 465
SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 466
UAE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 467
UAE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 468
UAE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 469
UAE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 470
UAE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 471
UAE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 472
UAE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 473
UAE: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 474
REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 475
REST OF GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 476
REST OF GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 477
REST OF GCC COUNTRIES: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 478
REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 479
REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 480
REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 481
REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 482
REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 483
REST OF MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 484
REST OF MIDDLE EAST: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 485
REST OF MIDDLE EAST: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 486
REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 487
REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 488
REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 489
REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 490
AFRICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
TABLE 491
AFRICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 492
AFRICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 493
AFRICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 494
AFRICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 495
AFRICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 496
AFRICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 497
AFRICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 498
OVERVIEW OF STRATEGIES DEPLOYED BY MANUFACTURING COMPANIES, JANUARY 2021–APRIL 2025
TABLE 499
CELL-BASED ASSAYS MARKET: DEGREE OF COMPETITION
TABLE 500
CELL-BASED ASSAYS MARKET: OFFERING FOOTPRINT
TABLE 501
CELL-BASED ASSAYS MARKET: TECHNOLOGY FOOTPRINT
TABLE 502
CELL-BASED ASSAYS MARKET: APPLICATION FOOTPRINT
TABLE 503
CELL-BASED ASSAYS MARKET: REGION FOOTPRINT
TABLE 504
CELL-BASED ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 505
CELL-BASED ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 506
CELL-BASED ASSAYS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025
TABLE 507
CELL-BASED ASSAYS MARKET: DEALS, JANUARY 2021–APRIL 2025
TABLE 508
CELL-BASED ASSAYS MARKET: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 509
DANAHER: COMPANY OVERVIEW
TABLE 510
DANAHER: PRODUCTS/SERVICES OFFERED
TABLE 511
DANAHER: DEALS, JANUARY 2021–APRIL 2025
TABLE 512
DANAHER: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 513
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 514
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 515
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–APRIL 2025
TABLE 516
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 517
THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025
TABLE 518
MERCK KGAA: COMPANY OVERVIEW
TABLE 519
MERCK KGAA: PRODUCTS/SERVICES OFFERED
TABLE 520
MERCK KGAA: DEALS, JANUARY 2021–APRIL 2025
TABLE 521
MERCK KGAA: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 522
BD: BUSINESS OVERVIEW
TABLE 523
BD: PRODUCTS/SERVICES OFFERED
TABLE 524
BD: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025
TABLE 525
BD: DEALS, JANUARY 2021–APRIL 2025
TABLE 526
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 527
AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 528
AGILENT TECHNOLOGIES, INC.: PRODUCTS LAUNCHES, JANUARY 2021–APRIL 2025
TABLE 529
LONZA: COMPANY OVERVIEW
TABLE 530
LONZA: PRODUCTS/SERVICES OFFERED
TABLE 531
LONZA: DEALS, JANUARY 2021–APRIL 2025
TABLE 532
LONZA: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 533
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 534
EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
TABLE 535
EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–APRIL 2025
TABLE 536
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 537
CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 538
CHARLES RIVER LABORATORIES: SERVICE LAUNCHES, JANUARY 2021–APRIL 2025
TABLE 539
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–APRIL 2025
TABLE 540
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 541
BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 542
REVVITY: COMPANY OVERVIEW
TABLE 543
REVVITY: PRODUCTS/SERVICES OFFERED
TABLE 544
REVVITY: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025
TABLE 545
SARTORIUS AG: COMPANY OVERVIEW
TABLE 546
SARTORIUS AG: PRODUCTS/SERVICES OFFERED
TABLE 547
SARTORIUS AG: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 548
CORNING INCORPORATED: COMPANY OVERVIEW
TABLE 549
CORNING INCORPORATED: PRODUCTS/SERVICES OFFERED
TABLE 550
PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 551
PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 552
PROMEGA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025
TABLE 553
CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
TABLE 554
CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SERVICES OFFERED
TABLE 555
ENZO BIOCHEM INC.: COMPANY OVERVIEW
TABLE 556
ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED
TABLE 557
ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 558
CARNA BIOSCIENCES, INC.: BUSINESS OVERVIEW
TABLE 559
CARNA BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 560
INTERTEK GROUP PLC: COMPANY OVERVIEW
TABLE 561
INTERTEK GROUP PLC: PRODUCTS /SERVICES OFFERED
TABLE 562
INTERTEK GROUP PLC: EXPANSIONS, JANUARY 2021–APRIL 2025
TABLE 563
BICO: COMPANY OVERVIEW
TABLE 564
BICO: PRODUCTS/SERVICES OFFERED
LIST OF FIGURES
FIGURE 1
CELL-BASED ASSAYS MARKET: SEGMENTS & REGIONS CONSIDERED
FIGURE 2
RESEARCH DESIGN
FIGURE 3
BREAKDOWN OF PRIMARIES: CELL-BASED ASSAYS MARKET
FIGURE 4
CELL-BASED ASSAYS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 5
MARKET SIZE ESTIMATION: GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH), 2024
FIGURE 6
ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2024)
FIGURE 7
MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 8
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9
CELL-BASED ASSAYS MARKET: CAGR PROJECTIONS
FIGURE 10
DATA TRIANGULATION METHODOLOGY
FIGURE 11
CELL-BASED ASSAYS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
FIGURE 12
CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 13
CELL-BASED ASSAYS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 14
CELL-BASED ASSAYS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 15
GEOGRAPHICAL SNAPSHOT OF CELL-BASED ASSAYS MARKET
FIGURE 16
GROWING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET
FIGURE 17
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024
FIGURE 18
CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
FIGURE 19
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT HELD MAJOR MARKET SHARE IN 2024
FIGURE 20
ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 21
CELL-BASED ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22
AGE-STANDARDIZED RATE (WORLD) PER 100,000 CANCER INCIDENCES IN BOTH SEXES, 2022
FIGURE 23
CELL-BASED ASSAYS MARKET: VALUE CHAIN ANALYSIS
FIGURE 24
PRICING ANALYSIS FOR CELL-BASED ASSAY PRODUCTS, 2022–2024
FIGURE 25
CELL-BASED ASSAYS MARKET ECOSYSTEM
FIGURE 26
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 27
PATENT APPLICATION IN CELL-BASED ASSAYS MARKET, JANUARY 2014–APRIL 2025
FIGURE 28
CELL-BASED ASSAYS MARKET: PORTER’S FIVE ANALYSIS
FIGURE 29
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL-BASED ASSAY PRODUCTS
FIGURE 30
KEY BUYING CRITERIA FOR END USERS
FIGURE 31
CELL-BASED ASSAYS MARKET: INVESTMENT AND FUNDING SCENARIO, 2020-2024
FIGURE 32
IMPACT OF AI/GEN AI ON CELL-BASED ASSAYS MARKET
FIGURE 33
INSTRUMENTS MARKET (FLOW CYTOMETERS) FOR CELL-BASED ASSAYS, 2023–2030 (THOUSAND UNITS)
FIGURE 34
WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2021–2028
FIGURE 35
NORTH AMERICA: CELL-BASED ASSAYS MARKET SNAPSHOT
FIGURE 36
ASIA PACIFIC: CELL-BASED ASSAYS MARKET SNAPSHOT
FIGURE 37
REVENUE ANALYSIS OF KEY PLAYERS IN CELL-BASED ASSAYS MARKET (2020–2024)
FIGURE 38
MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL-BASED ASSAYS MARKET (2024)
FIGURE 39
CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 40
CELL-BASED ASSAYS MARKET: COMPANY FOOTPRINT
FIGURE 41
CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX, (STARTUPS/SMES), 2024
FIGURE 42
EV/EBITDA OF KEY VENDORS
FIGURE 43
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 44
CELL-BASED ASSAYS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 45
DANAHER: COMPANY SNAPSHOT (2024)
FIGURE 46
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 47
MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 48
BD: COMPANY SNAPSHOT (2024)
FIGURE 49
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 50
LONZA: COMPANY SNAPSHOT (2024)
FIGURE 51
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
FIGURE 52
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
FIGURE 53
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 54
REVVITY: COMPANY SNAPSHOT (2024)
FIGURE 55
SARTORIUS AG: COMPANY SNAPSHOT (2024)
FIGURE 56
CORNING INCORPORATED: COMPANY SNAPSHOT (2024)
FIGURE 57
ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2024)
FIGURE 58
CARNA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 59
INTERTEK GROUP PLC: COMPANY SNAPSHOT (2024)
FIGURE 60
BICO: COMPANY SNAPSHOT (2024)
Methodology
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell-based assays market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell-based assays market. The secondary sources used for this study include the American Society for Cell Biology (ASCB), Federal Ministry of Education and Research (BMBF), Center for Commercialization of Regenerative Medicine (CCRM), Centers for Disease Control and Prevention (CDC), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Agency for Research on Cancer (IARC), International Society for Advancement of Cytometry (ISAC), International Society for Stem Cell Research (ISSCR), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Cancer Research Fund International (WCRF), World Health Organization (WHO), and Eurostat; Statista; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations; among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
After acquiring foundational knowledge about the global cell-based assays market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutes. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned five major regions: Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. Approximately 60% of the primary interviews were conducted with supply-side participants, while the remaining 40% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell-based assays market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cell-based assays involve the use of cells to examine and assess different biochemical or cellular processes. These assays allow researchers to investigate the responses of cells under specific experimental conditions as well as to determine the effect of drugs on a particular cell line. These assays are also used to determine the potency of a drug by comparing the biological response related to its mode of action with that of a control preparation. Additionally, cell-based assays can be used in biomedical research and drug-discovery screening applications to quantify cytotoxicity, biological activity, biochemical mechanisms, and off-target interactions.
Stakeholders
- Cell-based assay, consumable, instrument, and software manufacturers
- Cell-based assay service providers
- Cell-based assay vendors and distributors
- Third-party suppliers, direct suppliers, distributors, and channel partners
- Venture capitalists
- Research & development (R&D) companies
- Pharmaceutical & biotechnology companies
- Research laboratories & academic institutes
- Clinical research organizations (CROs)
- Market research & consulting firms
- Government & independent regulatory authorities
Report Objectives
- To define, describe, and forecast the global cell-based assays market based on offering, technology, application, end user, and region
- To provide detailed information on the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets in terms of individual growth trends, future prospects, and contributions to the overall cell-based assays market
- To analyze opportunities in the global market for major stakeholders and provide a detailed competitive landscape for market leaders
- To forecast the size of the market segments with respect to six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To provide volume data for instruments used in cell-based assays
- To strategically profile the key players in the global cell-based assays market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments in the cell-based assays market, such as product launches, acquisitions, collaborations, expansions, and partnerships
- To benchmark players within the cell-based assays market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Cell Based Assays Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Cell Based Assays Market